Anlotinib Anticancer Drugs Oncology Pharmacology Physiotherapy

Anlotinib (Pharmacokinetics-1)

In this article we will discuss Anlotinib (Pharmacokinetics-1)

In this article, we will discuss Anlotinib (Pharmacokinetics-1). So, let’s get started.

The pharmacokinetic properties of anlotinib have been estimated in studies on animals and patients with advanced solid tumors.
The results of pharmacokinetic and disposition investigations in rats and dogs showed that anlotinib had good membrane permeability and was absorbed quickly. The oral bioavailability of anlotinib was 28–58% and 41–77% in rats and dogs, respectively. The biotransformation of anlotinib showed a significant difference between species, with a terminal half-life of 22.8 ± 11.0 h in dogs and 5.1 ± 1.6 h in rats. The difference appeared to be related to differences in total plasma clearance (rats, 5.35 ± 1.31 L/h/kg; dogs, 0.40
± 0.06 L/h/kg). Anlotinib had large apparent volumes of distribution in rats (27.6 ± 3.1 L/kg) and dogs (6.6 ± 2.5 L/kg). It was highly bound to plasma in all species, including rat (97%), dog (96%), and human (93%). In
human plasma, anlotinib was bound mainly to albumin and lipoproteins. The levels of anlotinib in the tissues of rats and tumor-bearing mice were significantly
higher than the corresponding level in the plasma.

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.